Retroperitoneal tumors are account for fewer than 0.2 % of total malignancies. Retroperitoneal leiomyosarcoma of these are rare and show a tendency toward large size and extensions by infiltration to the adjacent structure. Thus, the most frequent symptoms are palpable abdominal mass and abdominal pain. Early detection and treatment is difficult in retroperitoneal tumor. Aggressive radical surgical excision is treatment of choice. Modern therapeutic modalilty improve the prognosis, but still remained debatable prognosis. we report a case of retroperitoneal leiomyosarcoma in 54-year-old women who was recieved chemotherapy and then surgical removal.
Abdominal Pain ; Drug Therapy ; Female ; Humans ; Leiomyosarcoma* ; Middle Aged ; Prognosis

Contrary to metastatic tumors of the omentum, primary tumors of the omentum are very rare. A 10-year-old girl presented with low abdominal pain. Imaging studies showed a multiseptated hemorrhagic tumor. The mass from the omentum was removed completely and confirmed as a malignant rhabdoid tumor. Despite aggressive chemotherapy, she died after 9 months due to disease progression. We report one case of primary malignant rhabdoid tumor of the omentum for the first time.
Abdominal Pain ; Child* ; Disease Progression ; Drug Therapy ; Female* ; Humans ; Omentum* ; Rhabdoid Tumor*

Endometrioid stromal sarcoma of ovary is so rare that it has been reported 45 cases in the world. Endometrioid stromal sarcoma of ovary is concomitant with endometriosis at 40%, with same tumor in uterus at 30%. The age of pateint is between 11 and 76, half of them are fifties and sixties. Most frequent presenting symptom is abdominal distension and abdominal pain. Surgery, chemotherapy, radiotherapy, progesterone was helpful, but any management do not result in conclusion because of rarity of cases. Clinical course is indolent because lesion is well-differentiated and grows slowly, so only cytoreductive surgery will be effective. Progesterone may be effective in residual or recurrent low-grade endometrioid stromal sarcoma of ovary. If endometriotic tissue is origin of tumor, estrogen play a role in malignant transformation. We had experienced a case of endometrioid stromal sarcoma of ovary of 42 years old woman. We managed by TAH and BSO, radiotherapy, progesterone therapy. Until now no recurrence was found for 15 months. So, we report this case with review of the literature.
Abdominal Pain ; Adult ; Drug Therapy ; Endometriosis ; Estrogens ; Female ; Humans ; Ovary* ; Progesterone ; Radiotherapy ; Recurrence ; Sarcoma* ; Uterus

The standard treatment for epithelial ovarian cancer is maximal cytoreductive surgery and adjuvant chemotherapy. Neoadjuvant chemotherapy can be considered as an alternative treatment strategy when unacceptable primary surgery, in terms of gross residual tumor remaining at the end of cytoreduction, is expected or in cases where poor general condition renders extensive cytoreductive surgery unsuitable. Intraperitoneal chemotherapy is ideal for epithelial ovarian cancer because its spread is mainly limited to the peritoneal cavity. Several randomized controlled trials have reported a survival gain with intraperitoneal chemotherapy. However, disadvantages such as port-related complications, abdominal pain, and neurotoxicity hinder its wide use. Hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery has been suggested as an alternative treatment strategy for intraperitoneal chemotherapy. Ongoing clinical trials of hyperthermic intraperitoneal chemotherapy will quantify clinical outcomes in the future, such as the survival benefit in epithelial ovarian cancer.
Abdominal Pain ; Chemotherapy, Adjuvant ; Drug Therapy* ; Neoplasm, Residual ; Ovarian Neoplasms* ; Peritoneal Cavity

BACKGROUND/AIMS: The endoscopic and clinical findings of gastrointestinal (GI) Burkitt lymphoma in Koreans are not well known. METHODS: From January 1995 to July 2007, 80 patients (47 adults and 33 children) were diagnosed with Burkitt lymphoma at our institution. The clinical and endoscopic manifestations were analyzed in the adult patients (n=20, median age=52 yr) with GI Burkitt lymphoma. RESULTS: The most frequent symptom was abdominal pain (50%) followed by epigastic soreness (30%). Among the 20 patients with GI Burkitt lymphoma, 11 (55%) had gastric lesions, 4 (20%) had colonic lesions, 3 (15%) had both gastric and duodenal lesions, 1 (5%) had both gastric and colonic lesions, and 1 (5%) had gastric, duodenal and colonic lesions. For the 13 patients who had endoscopic pictures available, the most common type of disease was the ulcerative type (38.5%) followed by the ulcerofungating and ulceroinfiltrative types (23.1% and 23.1%, respectively). Most of the patients were diagnosed with advanced disease. The most common clinical stage was stage IVE (60%) by the Musshoff staging system. All 20 patients received combination chemotherapy, and the 5-year survival rate was 64%. CONCLUSIONS: For patients with GI Burkitt lymphoma, the most commonly involved site was the stomach. Most lesions were ulcerative with or without fungating morphology. Considering the advanced stage of most patients, the prognosis after systemic chemotherapy was favorable.
Abdominal Pain ; Adult ; Burkitt Lymphoma ; Colon ; Drug Therapy, Combination ; Humans ; Prognosis ; Stomach ; Survival Rate ; Ulcer

The primary leiomyosarcoma of the vagina is very rare tumor in the female lower genital tract. A case of primary leiomyosarcoma of the vagina in the 44 years old woman was presented with lower abdominal pain and cystic and solid mass in the vagina. The mass was mainly comprised with spindle shaped cells showing moderate degree of cellular atypia and mitosis up to 8/10HPF. The mainstay of treatment is surgical excision of the primary mass. Treatment with chemotherapy or radiation therapy usually reserved for inoperable or recurrent cases. We present this case with a review of literature.
Abdominal Pain ; Adult ; Drug Therapy ; Female ; Humans ; Leiomyosarcoma* ; Mitosis ; Sarcoma ; Vagina*

BACKGROUND/AIMS: This study evaluated the use and efficacy of chronic oral etoposide plus tamoxifen as a palliative treatment in 30 patients with far-advanced HCC in whom surgical resection, percutaneous ethanol injection or transarterial chemoembolization(TACE) was not possible. METHODS: To be eligible for the study, patients had to have objectively measurable or evaluable tumors, adequate hematologic profiles and hepatorenal functions, had to be between 20 and 75 years of age, and had to have an ECOG performance status of less than or equal to 2. The treatment included etoposide, 50 mg/m2/day, taken orally for 21 days, and tamoxifen, 40 mg/day, taken orally for 21 days. Each cycle was repeated every 5 weeks. RESULTS: Two patients(7%) achieved a partial response(PR) and 16 patients(53%) achieved a stable disease(SD) with a median time-to-progression of 5 months(range: 2-24). Median of patients survival with the response of PR or SD and those patients with the response of progressive disease(PD) was 10 months and 7 months, respectively(p=0.0004). Of the 20 patients with initial elevated serum alpha-fetoprotein(> or =500 ng/ml), 9 patients(45%) experienced a significant(> or =50%) decrease in their values after chemotherapy and all 9 patients achieved objective tumor response of more than or equal to SD. Among the 30 patients in the study, 10 patients(33%) achieved performance status improvements of grade according to the ECOG criteria and 6 patients(20%) experienced improvements of subjective symptoms, such as abdominal pain, abdominal fullness and anorexia. CONCLUSION: Based on our results, the use of chronic oral etoposide plus tamoxifen as a palliative treatment for the far-advanced hepatocellular carcinoma are beneficial. A randomized two-arm study may be warranted to validate the results of this study.
Abdominal Pain ; Anorexia ; Carcinoma, Hepatocellular* ; Drug Therapy ; Ethanol ; Etoposide* ; Humans ; Palliative Care ; Tamoxifen*

The authors report a xase of primary non-gestational choriocarcinoma(PNGCO) of the ovary in a prepubertal female patient and reviewed. It is an extremely rere disease of which incidence is one in 369 million. Major clinical symptom is abdominal pain, precociois puberty and it can be misdiagneosed as ectopic pergnancy. Distinction from gestational choriocarcinoma(GCO) of the ovary is important because of the worse prognosis of PNGCO. But no distinctive ultrastructural or immunohistochemical differences are found between PNGCO and GCO. Most acceptable treatment modality is an aggressive surgical therapy and systemic chemotherapy, but its progrosis is poor.
Abdominal Pain ; Adolescent ; Choriocarcinoma, Non-gestational* ; Drug Therapy ; Female ; Humans ; Incidence ; Ovary* ; Prognosis ; Puberty

The Shenghua Decoction recorded in Fu Qing Zhu's Gynaecology,is a commonly used postpartum prescription,widely used in treating postpartum and gynecological diseases. However,its mechanism of action in treating lower abdominal pain remains unclear. In this paper,network pharmacology was used to explore the mechanism of Shenghua Decoction in the treatment of lower abdomen pain,so as to provide data support for better clinical application of Shenghua Decoction. The drug targets of lower abdominal pain and Shenghua Decoction were retrieved in SymMap. String and Cytoscape were adopted for enrichment analysis to construct the disease-drug-target biological network. Relevant gene search results showed that there were 400 targets in Shenghua Decoction,11 of which coincided with the disease genes of lower abdomen pain. In String analysis,18 gene interactions were obtained. Gene modularizationbased analysis results indicated that one module containing six genes was obtained after modularization processing. Furthermore,there were 170 enrichment results of biological process,2 enrichment results of molecular function and 30 enrichment results of KEGG pathways in String enrichment analysis. Shenghua Decoction may play a role in treating lower abdomen pain through neuro-endocrine-immune,metabolism and other means. Its mechanism may be achieved by accelerating the repair and growth of endometrial tissue cells,improving microcirculation,promoting endometrial cell renewal and inflammation subsidence,and accelerating uterine involution; at the same time,it can regulate the autoimmunity,regulate and control the function of some natural immune cells in the process of antiinfection by using signaling pathway,supplement the vital energy,and induce elimination of pathogens from the body,thereby achieving the effect of treating lower abdomen pain.
Abdominal Pain ; drug therapy ; Drugs, Chinese Herbal ; pharmacology ; Female ; Gynecology ; Humans ; Signal Transduction

Desmoplastic small round cell tumor (DSRCT) is a distinct clinicopathologic entity that has only recently been described. This aggressive malignant small cell neoplasm tends to occur in adolescents and young adults, who may present with vague abdominal discomfort or distention. We report a case of DSRCT in a 13 year-old girl who presented with intermittent abdominal pain and bulky intra-abdominal mass, accompanied by an increased serum level of a tumor marker CA125. Clinical, pathological, immunohistochemical and radiologic features were compatible with DSRCT. She is under aggressive combination chemotherapy after surgical resection.
Abdominal Pain ; Adolescent ; Desmoplastic Small Round Cell Tumor* ; Drug Therapy ; Drug Therapy, Combination ; Female ; Humans ; Young Adult